Understanding risk: Women's perceived risk of menopause-related disease and the value they place on preventive hormone replacement therapy

Family Practice

Volumn 19, Issue 6, 2002, Pages 591-595

  Ballard, Karen ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Disease prevention; HRT; Menopause; Osteoporosis; Risk

Indexed keywords

STEROID HORMONE;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; FAMILY HISTORY; FEMALE; GENERAL PRACTITIONER; HEART DISEASE; HORMONE SUBSTITUTION; HUMAN; INTERVIEW; LIFESTYLE; MEDICAL DECISION MAKING; MENOPAUSE RELATED DISORDER; POSTMENOPAUSE OSTEOPOROSIS; QUALITATIVE ANALYSIS; RISK ASSESSMENT; SELF CONCEPT; TAPE RECORDER; UNITED KINGDOM;

EID: 0036899788     PISSN: 02632136     EISSN: None     Source Type: Journal    
DOI: 10.1093/fampra/19.6.591     Document Type: Article

References (17)

1. Misselbrook D, Armstrong D. Patients' response to risk information about the benefits of treating hypertension. Br J Gen Pract 2001; 51: 276-279.
2. Nexoe J, Gyrd-Hansen D, Kragstrup J, Kristiansen I, Nielsen J. Danish GPs' perception of disease risk and benefit of prevention. Fam Pract 2002; 19: 3-6.
3. Beck U. Risk Society: Towards a New Modernity. London: Sage, 1992.
4. Lupton D. Risk. London: Routledge, 1999.
5. Lindsay R, Hart DM, Aitken JM, MacDonald EB, Anderson JB, Clarke AC. Long-term prevention of postmenopausal osteoporosis by oestrogen. Evidence for an increased bone mass after delayed onset of oestrogen treatment. Lancet 1976; 1(7968): 1038-1041.
6. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence. Prev Med 1991; 20: 47-63.
7. Tang M, Jacobs D, Stern Y. Effects of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996; 348: 429-432.
8. Ballard K. Women's use of hormone replacement therapy for disease prevention: results of a community survey. Br J Gen Pract 2002; 52: 835-837.
9. Hulley S, Grady D, Bush T et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280: 605-613.
10. Writing group for the Women's Health Initiative Investigators. Risks and benefits of oestrogen plus progesterone in healthy post-menopausal women. JAMA 2002; 288: 321-333.
11. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 1997; 350: 1047-1059.
12. Grady D, Gebretsadik T, Kerlikowske K et al. Hormone replacement therapy and endometrial cancer risk: A meta-analysis. JAMA 1995; 85: 304-313.
13. Examples of clinical trials: Women's International Study of long-duration Oestrogen after Menopause (WISDOM), Heart and Estrogen/progestin Replacement Study (HERS), Postmenopausal Estrogen and Progestin Interventions (PEPI).
14. Williams SJ, Calnan M. The "limits" of medicalisation?: Modern medicine and the lay populace in "late" modernity. Soc Sci Med 1996; 42: 1609-1620.
15. Kuh DJ, Hardy R, Wadsworth MEJ. Social and behavioural. influences on the uptake of hormone replacement therapy among younger women. Br J Obst Gyn 2000; 107: 731-739.
16. Bryman A. Quality and Quantity in Social Research. London: Routledge, 1996.
17. Bryman A. Social Research Methods. Oxford: Oxford University Press, 2001.